SCHEMBL17615499

SCHEMBL17615499

CCCNC(=O)CCN(CCCN(CCO)CCO)CCC(=O)NCCC

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.47
DNM1 Q05193 2/20 0.46
GAA P10253 1/20 0.42
FAAH O00519 3/20 0.42
CASP2 P42575 1/20 0.42
CNR1 P21554 2/20 0.41
ICMT O60725 1/20 0.40
ALB P02768 1/20 0.40
SELP P16109 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
MEN1 O00255 1/20 0.39
KCNK3 O14649 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CNR2 P34972 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL889191 0.93 DNM1 (0.49) NAAADNM1GAAFAAHCASP2
SCHEMBL16638653 0.89 NAAA (0.65) NAAADNM1FAAHCASP2CNR1
SCHEMBL12792130 0.89 NAAA (0.65) NAAADNM1FAAHCASP2CNR1
SCHEMBL12792143 0.89 NAAA (0.65) NAAADNM1FAAHCASP2CNR1
SCHEMBL12791952 0.89 NAAA (0.65) NAAADNM1FAAHCASP2CNR1
SCHEMBL889199 0.87 DNM1 (0.51) NAAADNM1GAAFAAHCASP2
SCHEMBL16356885 0.87 NAAA (0.41) NAAADNM1GAAFAAHCASP2
SCHEMBL889316 0.86 NAAA (0.61) NAAADNM1FAAHCASP2CNR1
SCHEMBL889238 0.86 NAAA (0.61) NAAADNM1FAAHCASP2CNR1
SCHEMBL889317 0.86 NAAA (0.61) NAAADNM1FAAHCASP2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018080-B2 Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway THE BROAD INSTITUTE, INC. (US) 2024-06-25 US disclosed
US-20240018552-A1 NOVEL CRISPR ENZYMES AND SYSTEMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2024-01-18 US disclosed
US-20160082126-A1 NANOCOMPLEXES FOR DELIVERY OF SAPORIN UNIV TUFTS (US) 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018080-B2 Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway KLRK1, CD47, FCGR3B NAAA 4336/4885DNM1 3022/4885GAA 2067/4885
US-20240018552-A1 NOVEL CRISPR ENZYMES AND SYSTEMS CPSF1, CPSF6, CPN1 NAAA 2743/4885DNM1 3631/4885GAA 353/4885
US-20160082126-A1 NANOCOMPLEXES FOR DELIVERY OF SAPORIN SARNP, SAP30BP, SCP2 NAAA 3052/4885DNM1 3713/4885GAA 3427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.